Eye disease study lays groundwork for gene therapy breakthrough

NCT ID NCT04639635

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at a rare, inherited eye disease called CNGB1 retinitis pigmentosa that causes gradual vision loss and blindness. Researchers want to learn how the disease progresses by using eye exams and imaging tests over three years. The goal is to find the best ways to measure vision changes so that future gene therapy trials can be more effective. No treatment is given in this study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA ASSOCIATED WITH CNGB1 MUTATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinitis pigmentosa retinitis pigmentosa 45

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dr. Stephen H. Tsang

    New York, New York, 10032, United States

  • Eberhard Karls University Tubingen

    Tübingen, Germany

  • Institut de la Vision/Centre de maladies rares du Centre Hospitalier National Ophtalmologique des Quinze-Vingts

    Paris, France

  • Klinikum der Universität München University Eye Hospital, Ludwig-Maximilians-University (LMU) Munich

    München, Bavaria, 80336, Germany

  • Moorfields Eye Hospital NHS Foundation Trust

    London, United Kingdom

  • Wills Eye Hospital

    Philadelphia, Pennsylvania, 19107, United States